CY1697A - Novel pharmaceutical use of (NVA)2-cyclosporine - Google Patents

Novel pharmaceutical use of (NVA)2-cyclosporine

Info

Publication number
CY1697A
CY1697A CY169794A CY169794A CY1697A CY 1697 A CY1697 A CY 1697A CY 169794 A CY169794 A CY 169794A CY 169794 A CY169794 A CY 169794A CY 1697 A CY1697 A CY 1697A
Authority
CY
Cyprus
Prior art keywords
nva
cyclosporine
pharmaceutical use
novel pharmaceutical
novel
Prior art date
Application number
CY169794A
Other languages
English (en)
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB848419715A external-priority patent/GB8419715D0/en
Priority claimed from GB848419716A external-priority patent/GB8419716D0/en
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of CY1697A publication Critical patent/CY1697A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CY169794A 1984-08-02 1994-01-14 Novel pharmaceutical use of (NVA)2-cyclosporine CY1697A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB848419715A GB8419715D0 (en) 1984-08-02 1984-08-02 Organic compounds
GB848419716A GB8419716D0 (en) 1984-08-02 1984-08-02 Organic compounds

Publications (1)

Publication Number Publication Date
CY1697A true CY1697A (en) 1994-01-14

Family

ID=26288061

Family Applications (1)

Application Number Title Priority Date Filing Date
CY169794A CY1697A (en) 1984-08-02 1994-01-14 Novel pharmaceutical use of (NVA)2-cyclosporine

Country Status (8)

Country Link
EP (2) EP0365044A3 (fr)
AU (1) AU581010B2 (fr)
CY (1) CY1697A (fr)
DE (2) DE3580717D1 (fr)
DK (1) DK348385A (fr)
HK (1) HK106393A (fr)
PH (1) PH21235A (fr)
SG (1) SG17993G (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639724A (en) 1984-07-24 1997-06-17 Sandoz Ltd. Cyclosporin galenic forms
JP2577049B2 (ja) * 1987-06-04 1997-01-29 三共株式会社 シクロスポリン製剤
WO1989001772A1 (fr) * 1987-09-03 1989-03-09 University Of Georgia Research Foundation, Inc. Composition de cyclosporine oculaire
EP0327280B1 (fr) * 1988-01-29 1992-03-18 Sankyo Company Limited Compositions contenant de la cyclosporine
US6007840A (en) * 1988-09-16 1999-12-28 Novartis Ag Pharmaceutical compositions comprising cyclosporins
KR0148748B1 (ko) * 1988-09-16 1998-08-17 장 크라메르, 한스 루돌프 하우스 사이클로스포린을 함유하는 약학조성물
US7081445B2 (en) 1989-02-20 2006-07-25 Novartis Ag Cyclosporin galenic forms
US6262022B1 (en) 1992-06-25 2001-07-17 Novartis Ag Pharmaceutical compositions containing cyclosporin as the active agent
SG45449A1 (en) 1992-05-13 1998-01-16 Sandoz Ltd Ophthalmic compositions
DK0589843T3 (da) 1992-09-25 2002-04-02 Novartis Ag Cyclosporinholdige farmaceutiske præparater
JP3862273B2 (ja) * 1993-04-20 2006-12-27 ノバルティス アクチエンゲゼルシャフト 経口投与用シクロスポリン含有新規製剤
JP3833248B2 (ja) 1994-11-03 2006-10-11 ノバルティス・アクチエンゲゼルシャフト 簡単な組成及び高い生物有効性を有する経口投与のためのシクロスポリンの新規処方物及びその製造法
DE19544507B4 (de) 1995-11-29 2007-11-15 Novartis Ag Cyclosporin enthaltende Präparate
CN1130373C (zh) * 1996-09-13 2003-12-10 诺瓦蒂斯有限公司 [3'－脱氧－3'－氧代－MeBmt]'环孢菌素制备方法
AU737053B2 (en) 1997-01-30 2001-08-09 Novartis Ag Oil-free pharmaceutical compositions containing cyclosporin A
US7732404B2 (en) 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
US7842791B2 (en) * 2002-12-19 2010-11-30 Nancy Jean Britten Dispersible pharmaceutical compositions
US6979672B2 (en) 2002-12-20 2005-12-27 Polichem, S.A. Cyclosporin-based pharmaceutical compositions
DE10356378A1 (de) * 2003-12-03 2005-06-30 Continental Aktiengesellschaft Verfahren zur Funktionssteuerung eines elektronischen Fahrstabilitätsprogramms für ein Kraftfahrzeug
WO2009042892A1 (fr) * 2007-09-26 2009-04-02 Oregon Health & Science University Undécapeptides cycliques et leurs dérivés comme thérapies pour la sclérose en plaques

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2819094A1 (de) * 1977-05-10 1978-11-23 Sandoz Ag Cyclosporin-derivate, ihre verwendung und herstellung
SE448386B (sv) * 1978-10-18 1987-02-16 Sandoz Ag Nya cyklosporinderivat, forfarande for framstellning av dem samt farmaceutisk komposition innehallande dem
AU558155B2 (en) * 1982-02-01 1987-01-22 Sandoz Ltd. Treating multiple sclerosis with dihydro-cyclosporin d

Also Published As

Publication number Publication date
EP0365044A3 (fr) 1990-08-22
SG17993G (en) 1993-04-16
EP0170623B1 (fr) 1990-11-28
EP0365044A2 (fr) 1990-04-25
EP0170623A2 (fr) 1986-02-05
EP0170623A3 (en) 1987-10-28
DK348385D0 (da) 1985-07-31
PH21235A (en) 1987-08-21
AU4563185A (en) 1986-02-06
DE3526545A1 (de) 1986-02-13
HK106393A (en) 1993-10-15
DE3580717D1 (de) 1991-01-10
AU581010B2 (en) 1989-02-09
DK348385A (da) 1986-02-03

Similar Documents

Publication Publication Date Title
GB2231265B (en) Therapeutic use of serotonin-antagonists
SG17993G (en) Novel pharmaceutical use of(nva)2-cyclosporine
IL75533A (en) Preparation of heteroaryloxyacetamides
GB8507789D0 (en) Preparation of 2-amino-s-triazines
IL76249A0 (en) Preparation of fluoroformates
GB8727401D0 (en) Preparation of trifluoromethylbenzonitrile
DE3566540D1 (en) Preparation of fluoropyridines
AU585890B2 (en) Pharmaceutical use of somatostatin analogues
IL82218A0 (en) Preparation of 1-aryl-5-amino-pyrazoles
IL74168A0 (en) 1alpha-hydroxyvitamin d2 analogs and pharmaceutical compositions containing them
IL82217A0 (en) Preparation of 1-aryl-5-amino-pyrazoles
GB2196961B (en) Preparation of polyfluoroenolates
GB8601724D0 (en) Application of tetracyano-quinodimethanes
IL76216A0 (en) Preparation of sulphonylisoureas and-thioureas
GB8520403D0 (en) Preparation of aminolactone
GB8422162D0 (en) Preparation of alkyfurans
ZA855872B (en) Novel pharmaceutical use of(nva)2-and dihydro-(val)2-cyclosporins
GB8708603D0 (en) Preparation of()-13-norfaranal
IL75926A0 (en) Somatostatin analogs and pharmaceutical compositions containing them
GB8802972D0 (en) Triperfluoroalkylamines & preparation of same
IL83517A (en) Preparation of n-cyano-methylarylcarboxamides
IL82018A0 (en) Preparation of 4-nitrophenetol
GB8613066D0 (en) Protection of proteins &c
GB8704561D0 (en) Application of tetrathiafulvalenes
IL91357A0 (en) Pharmaceutical formulations containing certain benzimi-azolylmethyl benzenamides